94 related articles for article (PubMed ID: 21190865)
1. Increased serum TWEAK levels in Psoriatic arthritis: relationship with disease activity and matrix metalloproteinase-3 serum levels.
Xia L; Shen H; Xiao W; Lu J
Cytokine; 2011 Mar; 53(3):289-91. PubMed ID: 21190865
[TBL] [Abstract][Full Text] [Related]
2. Elevation of human tumor necrosis factor-like weak inducer of apoptosis in peripheral blood mononuclear cells is correlated with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
Liu ZC; Zhou QL; Li XZ; Yang JH; Ao X; Veeraragoo P; Zuo XX
Cytokine; 2011 Mar; 53(3):295-300. PubMed ID: 21163672
[TBL] [Abstract][Full Text] [Related]
3. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
Park MC; Chung SJ; Park YB; Lee SK
Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
[TBL] [Abstract][Full Text] [Related]
4. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis.
Fraser A; Fearon U; Reece R; Emery P; Veale DJ
Arthritis Rheum; 2001 Sep; 44(9):2024-8. PubMed ID: 11592363
[TBL] [Abstract][Full Text] [Related]
6. Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis.
Shibata S; Tada Y; Komine M; Hattori N; Osame S; Kanda N; Watanabe S; Saeki H; Tamaki K
J Dermatol Sci; 2009 Jan; 53(1):34-9. PubMed ID: 18752933
[TBL] [Abstract][Full Text] [Related]
7. High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis.
Antonelli A; Fallahi P; Delle Sedie A; Ferrari SM; Maccheroni M; Bombardieri S; Riente L; Ferrannini E
Autoimmunity; 2008 Nov; 41(7):537-42. PubMed ID: 18855195
[TBL] [Abstract][Full Text] [Related]
8. Serum chemokines in patients with psoriatic arthritis treated with cyclosporin A.
Macchioni P; Boiardi L; Meliconi R; Pulsatelli L; Maldini MC; Ruggeri R; Facchini A; Salvarani C
J Rheumatol; 1998 Feb; 25(2):320-5. PubMed ID: 9489827
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis.
Mahmoud RK; El-Ansary AK; El-Eishi HH; Kamal HM; El-Saeed NH
Ital J Biochem; 2005; 54(3-4):248-57. PubMed ID: 16688934
[TBL] [Abstract][Full Text] [Related]
10. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis.
Danning CL; Illei GG; Hitchon C; Greer MR; Boumpas DT; McInnes IB
Arthritis Rheum; 2000 Jun; 43(6):1244-56. PubMed ID: 10857783
[TBL] [Abstract][Full Text] [Related]
11. TWEAK-binding autoantibodies are generated during psoriatic arthritis and are not influenced by anti-TNF therapy.
Guis S; Berbis P; Stephan D; Bertin D; Amatore F; Balandraud N; Lesavre N; Desplat-Jégo S
J Transl Med; 2016 Jun; 14(1):185. PubMed ID: 27338143
[TBL] [Abstract][Full Text] [Related]
12. Gelatinase expression and activity in the synovium and skin of patients with erosive psoriatic arthritis.
Hitchon CA; Danning CL; Illei GG; El-Gabalawy HS; Boumpas DT
J Rheumatol; 2002 Jan; 29(1):107-17. PubMed ID: 11824946
[TBL] [Abstract][Full Text] [Related]
13. Patterns of cytokine production in psoriatic synovium.
Ritchlin C; Haas-Smith SA; Hicks D; Cappuccio J; Osterland CK; Looney RJ
J Rheumatol; 1998 Aug; 25(8):1544-52. PubMed ID: 9712099
[TBL] [Abstract][Full Text] [Related]
14. Proinflammatory effects of tumour necrosis factor-like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts.
Hosokawa Y; Hosokawa I; Ozaki K; Nakae H; Matsuo T
Clin Exp Immunol; 2006 Dec; 146(3):540-9. PubMed ID: 17100776
[TBL] [Abstract][Full Text] [Related]
15. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation.
Fraser A; Fearon U; Billinghurst RC; Ionescu M; Reece R; Barwick T; Emery P; Poole AR; Veale DJ
Arthritis Rheum; 2003 Nov; 48(11):3085-95. PubMed ID: 14613270
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of TWEAK in patients with psoriasis vulgaris.
Bilgiç Ö; Sivrikaya A; Toker A; Ünlü A; Altınyazar C
Cytokine; 2016 Jan; 77():10-3. PubMed ID: 26499979
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 8 and monocyte chemoattractant protein-1 in patients with juvenile rheumatoid arthritis. Relation to onset types, disease activity, and synovial fluid leukocytes.
De Benedetti F; Pignatti P; Bernasconi S; Gerloni V; Matsushima K; Caporali R; Montecucco CM; Sozzani S; Fantini F; Martini A
J Rheumatol; 1999 Feb; 26(2):425-31. PubMed ID: 9972980
[TBL] [Abstract][Full Text] [Related]
18. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid.
Partsch G; Steiner G; Leeb BF; Dunky A; Bröll H; Smolen JS
J Rheumatol; 1997 Mar; 24(3):518-23. PubMed ID: 9058659
[TBL] [Abstract][Full Text] [Related]
19. Soluble TWEAK is markedly elevated in hemophagocytic lymphohistiocytosis.
Nagasawa M; Yi Z; Imashuku S; Nonoyama S; Ogawa K; Okumura K; Mizutani S
Am J Hematol; 2008 Mar; 83(3):222-5. PubMed ID: 17918252
[TBL] [Abstract][Full Text] [Related]
20. Elevated circulating TWEAK levels in systemic sclerosis: association with lower frequency of pulmonary fibrosis.
Yanaba K; Yoshizaki A; Muroi E; Hara T; Ogawa F; Usui A; Hasegawa M; Fujimoto M; Takehara K; Sato S
J Rheumatol; 2009 Aug; 36(8):1657-62. PubMed ID: 19531747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
